Pitolisant for treating patients with narcolepsy

References

• Chaiard J, Weaver TE. Update on research and practices in major sleep disorders: part II-insomnia, Willis-Ekbom disease (restless leg syndrome), and narcolepsy. J Nurs Scholarsh. 2019;51(6):624-633.
   Web of Science ®Google Scholar
• Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654.
   PubMed Web of Science ®Google Scholar
• Scheer D, Schwartz SW, Parr M, et al. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. Sleep. 2019;42(7):zsz091.
   PubMed Web of Science ®Google Scholar
• Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019 Sep;15(9):519–539.
   PubMed Web of Science ®Google Scholar
• Franceschini C, Pizza F, Antelmi E, et al. Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. Sleep Breath. 2019 Jul 10. [Epub ahead of print].
   PubMedGoogle Scholar
• Reading PJ. Update on narcolepsy. J Neurol . 2019;266(7):1809–1815.
   PubMed Web of Science ®Google Scholar
• de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother . 2019;20(5):483–486.
   PubMed Web of Science ®Google Scholar
• Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2018 Oct 19. [Epub ahead of print].
   PubMedGoogle Scholar
• Bassetti CL, Baumann CR, Dauvilliers Y, et al. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res. 2010;19(4):620–623.
   PubMed Web of Science ®Google Scholar
• Franco P, Dauvilliers Y, Inocente CO, et al. Impaired histaminergic neurotransmission in children with narcolepsy type 1. Impaired histaminergic neurotransmission in children with narcolepsy type 1. CNS Neurosci Ther. 2019;25(3):386–395.
   PubMed Web of Science ®Google Scholar
• Romigi A, Vitrani G, Lo Giudice T, et al. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:2665.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Clinical review. [cited 2019 Oct 14]. Available from. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000MedR.pdf.
   Google Scholar
• U.S. Food and Drug Administration. WAKIX (pitolisant) tablets, for oral use. [cited 2019 Oct 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf.
   Google Scholar
• Reading P. Cataplexy. Pract Neurol. 2019;19(1):21–27.
   PubMedGoogle Scholar
• Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23–26.
   PubMed Web of Science ®Google Scholar
• Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother . 2019;20(10):1189–1199.
   PubMed Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol. 2016;18(10):43.
   PubMed Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369–379.
   PubMed Web of Science ®Google Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39–47.
   PubMed Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(10):43.
   PubMed Web of Science ®Google Scholar
• Carter LP, Henningfield JE, Wang YG, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol,a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351–1361.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Feldman N, Emsellem HA, et al. of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–1108.
   PubMed Web of Science ®Google Scholar
• Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019;12(8):723–728.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. SUNOSI (solriamfetol) tablets, for oral use. [cited 2019 Oct 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
   Google Scholar
• Thorpy MJ, Shapiro C, Mayer G, et al. Randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–370.
   PubMed Web of Science ®Google Scholar
• Mahoney CE, Cogswell A, Koralnik IJ. et al. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83–93.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Q, Ji B, et al. The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220.
   PubMed Web of Science ®Google Scholar
• Nepovimova E, Janockova J, Misik J, et al. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev. 2019 May;39(3):961–965.
   PubMed Web of Science ®Google Scholar
• Burgess CR. Histamine and orexin in the control of arousal, locomotion, and motivation. J Neurosci. 2010. 24. 30(8):2810–2811.
   PubMed Web of Science ®Google Scholar
• Riddy DM, Cook AE, Shackleford DM, et al. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology. 2019;144:244–245.
   PubMed Web of Science ®Google Scholar
• Calik MW. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nat Sci Sleep. 2017;9:127–133.
   PubMed Web of Science ®Google Scholar
• Baumann CR. Wide implications of a trial on pitolisant for cataplexy. Lancet Neurol. 2017;16(3):173–174.
   PubMed Web of Science ®Google Scholar
• Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713–721.
   PubMed Web of Science ®Google Scholar
• Ligneau X, Landais L, Perrin D, et al. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol. 2007;73(8):1215–1224.
   PubMed Web of Science ®Google Scholar
• Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55.
   PubMed Web of Science ®Google Scholar
• Kollb-Sielecka M, Demolis P, Emmerich J, et al. The European medicines agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med. 2017;33:125–129.
   PubMed Web of Science ®Google Scholar
• Ghamari N, Zarei O, Arias-Montaño JA, et al. Histamine H receptor antagonists/inverse agonists: where do they go? Pharmacol Ther. 2019;200:69–74.
   PubMed Web of Science ®Google Scholar
• Scolnick B. Antihistamine agents and pitolisant might be useful for anorexia nervosa. Med Hypotheses. 2019;132:109342.
   PubMed Web of Science ®Google Scholar
• Ligneau X, Shah RR, Berrebi-Bertrand I, et al. Nonclinical cardiovascular safety of pitolisant: comparing international conference on harmonization S7B and comprehensive in vitro proarrhythmia assay initiative studies. Br J Pharmacol. 2017;174(23):4449–4463.
   PubMed Web of Science ®Google Scholar
• Syed YY. Pitolisant: first global approval. Drugs. 2016;76(13):1313–1318.
   PubMed Web of Science ®Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30(1):74–83.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy a double-blind, randomised trial. Lancet Neurol . 2013;12(11):1068–1075.
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200–207.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long -term use of pitolisant to treat patients with narcolepsy: harmony III Study. Sleep. 2019 21;42(11):zsz174.
   PubMed Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41(12).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Wakix (pitolisant): summary of product characteristics. [cited 2019 Oct 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wakix
   Google Scholar
• Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320:365–375.
   PubMed Web of Science ®Google Scholar
• Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol. 2013;169(3):632–634.
   PubMed Web of Science ®Google Scholar
• Huyts B, Brabant C, Tirelli E. Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol. 2019;851:63–68.
   PubMed Web of Science ®Google Scholar
• Brabant C, Charlier Y, Navacerrada MES, et al. Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice. Eur J Pharmacol. 2016;791:552–559.
   PubMed Web of Science ®Google Scholar
• Setnik B, McDonnell M, Mills C, et al. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2019 Oct 18. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Shah RR, Maison-Blanche P, Robert P, et al. Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist. Eur J Clin Pharmacol. 2016;72(5):533–543.
   PubMed Web of Science ®Google Scholar
• Scolnick B. Antihistamine agents and pitolisant might be useful for anorexia nervosa. Med Hypotheses. 2019 Jul 30;132:109342. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité D, Parain D, Genton P, et al. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Epilepsy Behav. 2013;28(1):66.
   PubMed Web of Science ®Google Scholar
• Collart Dutilleul P, Ryvlin P, Kahane P, et al. Exploratory phase II trial to evaluate the safety and the antiepileptic effect of pitolisant (BF2.649) in refractory partial seizures, given as adjunctive treatment during 3 months. Clin Neuropharmacol. 2016;39(4):188–193.
   PubMed Web of Science ®Google Scholar